(Q34088640)

English

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

author name string

Gotto AM Jr

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Boccuzzi SJ

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cook JR

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alexander CM

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Roehm JB

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Meyer GS

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Clearfield M

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Weis S

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Whitney E

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

86

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1176-1181

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Range of serum cholesterol values in the population developing coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Benefit and costs of anti-hypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Antihypertensive therapy: how to evaluate the benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Analyses of cost effectiveness in the management of essential hypertension: what they can and what they do not teach us.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901198-X

7 January 2021

Identifiers

10.1016/S0002-9149(00)01198-X

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34088640&oldid=1958255248"